Sinovac Biotech Ltd

Sinovac Biotech Ltd

Sinovac Biotech Ltd was founded in 2001 by Weidong Yin, a biologist and entrepreneur who previously worked at China's National Institute for the Control of Pharmaceutical and Biological Products. The company is headquartered in Beijing and develops vaccines for infectious diseases, including hepatitis A and B, influenza, hand-foot-and-mouth disease (EV71), and COVID-19. Sinovac's core asset — its inactivated vaccine platform — underpins its production pipeline (per company filings). Sinovac focuses on whole-virion inactivated virus vaccines, which rely on traditional, well-understood manufacturing processes. Its most recognized product, CoronaVac, received emergency use authorization in over 50 countries starting in 2021, with the World Health Organization (WHO) granting Emergency Use Listing in June 2021. The company also markets vaccines for hepatitis A under the brand Healive and for EV71 (hand, foot, and mouth disease) as Inlive. Sinovac has not publicly disclosed AUM or assets under management, as it is a publicly traded biotech firm, not an investment fund. The firm employs roughly 4,000 people as of late 2023, per its annual report. Its manufacturing network includes facilities in Beijing and Xuzhou, China, with a combined annual production capacity of over one billion doses. Sinovac maintains a philanthropic focus via its charitable initiatives, though separated from its commercial operations. Sinovac's structural differentiator lies in its role as a state-supported yet publicly listed vaccine developer — balancing government procurement contracts (especially for emerging market supply) with Western institutional shareholder demands. Unlike many biotech peers that license technology, Sinovac controls its entire inactivated-vaccine production chain, from viral seed stocks to fill-finish, giving it supply-chain leverage in global health emergencies.